Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics Inc reported $62.4M in revenue and a $101.6M net loss for fiscal 2025.
See the full TNGX financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics (TNGX) granted inducement equity awards to a new employee effective September 1, 2026, under its 2023 Inducement Plan.
Tango Therapeutics (TNGX) granted inducement equity awards to a new employee effective September 1, 2026, under its 2023 Inducement Plan.
The package consists of a non-qualified stock option for 146,500 shares of common stock and 40,000 RSUs, granted pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options carry an exercise price of $22.35 per share, equal to the closing price of Tango Therapeutics’ common stock on September 1, 2026. Options vest 25% on the first anniversary of the employee’s start date and 1/36 of the remaining shares monthly thereafter, subject to continued employment. The RSUs vest in three equal annual installments, also conditioned on continued employment. All awards are governed by the terms of the company’s 2023 Inducement Plan, approved in February 2023, and the related grant agreements.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
TNGX was down -0.13% before publication, while three scanner peers were listed up with 0% changes. T...
Analysis
TNGX was down -0.13% before publication, while three scanner peers were listed up with 0% changes. That divergence frames the grant as company-specific context; high short positioning and net insider selling were risks to monitor.
Tango priced an upsized offering expected to generate $600 million in gross proceeds.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
All five selected historical events had negative 24-hour reactions; reactions aligned with negative offerings and leadership changes but diverged from positive or informational announcements.
Key Terms
non-qualified stock option, restricted stock units, inducement plan
3 terms
non-qualified stock optionfinancial
"granted a non-qualified stock option to purchase 146,500 shares"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
restricted stock unitsfinancial
"and 40,000 restricted stock units (RSUs) to a new employee"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
inducement planregulatory
"under Tango Therapeutics' 2023 Inducement Plan"
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 146,500 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.
The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
The options have an exercise price of $22.35 per share, which is equal to the closing price of Tango Therapeutics' common stock on September 1, 2026.Each option will vest as to 25% of the shares underlying such option on the first anniversary of the employee’s start date and as to an additional 1/36th of the remaining shares underlying the option monthly thereafter, in each case, subject to the employee's continued employment on each vesting date.The RSU award will vest in three equal annual installments, subject to the employee's continued employment on each vesting date. The options and RSUs are subject to the terms and conditions of Tango Therapeutics' 2023 Inducement Plan, which was approved in February 2023, and the terms and conditions of the stock option and RSU agreements covering the grant.
AboutTangoTherapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
What inducement equity awards did Tango Therapeutics (TNGX) grant on September 1, 2026?
Tango Therapeutics granted a non-qualified stock option to purchase 146,500 shares of common stock and 40,000 restricted stock units (RSUs) to a new employee as an inducement award under its 2023 Inducement Plan.
What is the exercise price of the new Tango Therapeutics (TNGX) stock options?
The non-qualified stock options have an exercise price of $22.35 per share, which is equal to the closing price of Tango Therapeutics’ common stock on September 1, 2026.
How do the new Tango Therapeutics (TNGX) stock options vest?
Each option vests as to 25% of the underlying shares on the first anniversary of the employee’s start date, and as to an additional 1/36 of the remaining shares monthly thereafter, subject to the employee’s continued employment on each vesting date.
What is the vesting schedule for the new Tango Therapeutics (TNGX) RSU grant?
The 40,000 RSUs granted to the new employee vest in three equal annual installments, with each installment subject to the employee’s continued employment on the applicable vesting date.
Under which plan and Nasdaq rule were the Tango Therapeutics (TNGX) inducement grants made?
The awards were granted under the Tango Therapeutics 2023 Inducement Plan, used exclusively for inducement equity grants pursuant to Nasdaq Listing Rule 5635(c)(4), which permits equity awards as a material inducement to entering employment.
